10 research outputs found
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies
PURPOSE: Sotatercept may represent a novel approach to the treatment of chemotherapy-induced anemia (CIA). We report the results from two phase 2 randomized studies examining the use of sotatercept for the treatment of CIA in patients with metastatic cancer. METHODS: In study A011-08, patients with metastatic breast cancer were randomized to 2:2:2:1 to receive sotatercept 0.1, 0.3, or 0.5 mg/kg, or placebo, respectively, every 28 days. In study ACE-011-NSCL-001, patients with solid tumors treated with platinum-based chemotherapy received sotatercept 15 or 30 mg every 42 days. The primary endpoint for both studies was hematopoietic response, defined as a hemoglobin (Hb) increase of \u3e/=1 g/dL from baseline. RESULTS: Both studies were terminated early due to slow patient accrual. Among patients treated with sotatercept in the A011-08 and ACE-011-NSCL-001 studies, more patients achieved a mean Hb increase of \u3e/=1 g/dL in the combined sotatercept 0.3 mg/kg and 15 mg (66.7 %) group and sotatercept 0.5 mg/kg and 30 mg (38.9 %) group versus the sotatercept 0.1 mg/kg (0 %) group. No patients achieved a mean Hb increase of \u3e/=1 g/dL in the placebo group. The incidence of treatment-related adverse events (AEs) was low in both studies, and treatment discontinuations due to AEs were uncommon. CONCLUSIONS: Although both studies were terminated early, these results indicate that sotatercept is active and has an acceptable safety profile in the treatment of CIA
Factors associated with long term survival of patients with metastatic adenocarcinoma of the lung.
Clinical Predictors of Metastatic Disease to the Brain from Non–Small Cell Lung Carcinoma: Primary Tumor Size, Cell Type, and Lymph Node Metastases
Activin receptor antagonists for cancer-related anemia and bone disease
Introduction: Antagonists of activin receptor signaling may be
beneficial for cancer-related anemia and bone disease caused by
malignancies such as multiple myeloma and solid tumors.
Areas covered: We review evidence of dysregulated signaling by activin
receptor pathways in anemia, myeloma-associated osteolysis, and
metastatic bone disease, as well as potential involvement in
carcinogenesis. We then review properties of activin receptor
antagonists in clinical development.
Expert opinion: Sotatercept is a novel receptor fusion protein that
functions as a soluble trap to sequester ligands of activin receptor
type IIA (ActRIIA). Preclinically, the murine version of sotatercept
increased red blood cells (RBC) in a model of chemotherapy-induced
anemia, inhibited tumor growth and metastasis, and exerted anabolic
effects on bone in diverse models of multiple myeloma. Clinically,
sotatercept increases RBC markedly in healthy volunteers and patients
with multiple myeloma. With a rapid onset of action differing from
erythropoietin, sotatercept is in clinical development as a potential
first-in-class therapeutic for cancer-related anemia, including those
characterized by ineffective erythropoiesis as in myelodysplastic
syndromes. Anabolic bone activity in early clinical studies and
potential antitumor effects make sotatercept a promising therapeutic
candidate for multiple myeloma and malignant bone diseases. Antitumor
activity has been observed preclinically with small-molecule inhibitors
of transforming growth factor-beta receptor type I (ALK5) that also
antagonize the closely related activin receptors ALK4 and ALK7.
LY-2157299, the first such inhibitor to enter clinical studies, has
shown an acceptable safety profile so far in patients with advanced
cancer. Together, these data identify activin receptor antagonists as
attractive therapeutic candidates for multiple diseases
Recommended from our members